Baseline characteristics
| Characteristic . | All BR patients . | Patients ≤65 y of age at chemotherapy . | Patients >65 y of age at chemotherapy . | ||||
|---|---|---|---|---|---|---|---|
| BR, n = 190 . | BR, n = 89 . | R-CHOP, n = 142 . | P . | BR, n = 101 . | R-CHOP, n = 106 . | P . | |
| Median age (range), y | 66 (37-90) | 58 (37-65) | 57 (31-65) | .282 | 73 (63-90) | 72 (63-87) | .631 |
| Male | 121 (64) | 55 (62) | 110 (78) | .010 | 66 (65) | 74 (70) | .493 |
| Performance status >1 | 36/158 (23) | 16/77 (21) | 23/136 (17) | .483 | 20/81 (25) | 31/93 (33) | .212 |
| Elevated LDH | 40/140 (29) | 24/71 (34) | 45/127 (35) | .817 | 16/69 (23) | 31/83 (37) | .060 |
| Ann Arbor stage III/IV | 166/180 (92) | 79/84 (94) | 129/142 (91) | .390 | 87/96 (91) | 95/103 (93) | .685 |
| Marrow/blood involvement | 132 (69) | 65 (73) | 113 (80) | .250 | 67 (66) | 73 (69) | .697 |
| B symptoms | 41/180 (23) | 22/84 (26) | 46/142 (32) | .326 | 19/96 (20) | 26/103 (25) | .358 |
| Largest mass ≥5 cm | 52/109 (48) | 24/52 (46) | 60/123 (49) | .751 | 28/57 (49) | 46/85 (54) | .559 |
| MIPI | |||||||
| High risk | 21/125 (17) | 9/64 (14) | 14/122 (12) | .519 | 12/61 (20) | 31/74 (42) | .007 |
| Intermediate risk | 38/125 (30) | 14/64 (22) | 20/122 (16) | 24/61 (39) | 28/74 (38) | ||
| Low risk | 66/125 (53) | 41/64 (64) | 88/122 (72) | 25/61 (41) | 15/74 (20) | ||
| Blastoid/pleomorphic | 13 (7) | 7 (8) | 14 (10) | .608 | 6 (6) | 15 (14) | .051 |
| Median Ki67 (range) | 30 (5-90) | 25 (5-90) | 25 (1-99) | .317 | 30 (5-90) | 33 (2-100) | .192 |
| Ki67 ≥30% | 92/171 (54) | 36/80 (45) | 42/88 (48) | .723 | 56/91 (62) | 34/64 (53) | .296 |
| Ki67 ≥50% | 45/171 (26) | 17/80 (21) | 26/88 (30) | .218 | 28/91 (31) | 22/64 (34) | .636 |
| Prior observation | 21 | 7 (8) | 6 (4) | .243 | 14 (14) | 6 (6) | .046 |
| Prior local therapy | 6 | 1 (1) | 3 (3) | 1.0 | 5 (5) | 1 (1) | .112 |
| Median no. of chemotherapy cycles (range) | 6 (1-6) | 6 (1-6) | 6 (1-8) | .127 | 6 (1-6) | 6 (1-8) | .890 |
| ≥6 cycles of chemotherapy | 154 (81) | 78 (88) | 123 (87) | .822 | 76 (75) | 82 (77) | .721 |
| ASCT | 71 (37) | 61 (69) | 81 (57) | .081 | 10 (10) | 5 (5) | .150 |
| Rituximab maintenance | 141 (74) | 72 (81) | 80 (56) | <.001 | 72 (71) | 25 (24) | <.001 |
| Rituximab maintenance protocol | |||||||
| Weekly × 4 doses ×2 cycles | 31/141 (22) | 27/72 (37) | 73/80 (91) | <.001 | 5/72 (7) | 5/25 (20) | .064 |
| Every 3 mo ×8 cycles | 110/141 (78) | 45/72 (63) | 7/80 (9) | 67/72 (93) | 20/25 (80) | ||
| Characteristic . | All BR patients . | Patients ≤65 y of age at chemotherapy . | Patients >65 y of age at chemotherapy . | ||||
|---|---|---|---|---|---|---|---|
| BR, n = 190 . | BR, n = 89 . | R-CHOP, n = 142 . | P . | BR, n = 101 . | R-CHOP, n = 106 . | P . | |
| Median age (range), y | 66 (37-90) | 58 (37-65) | 57 (31-65) | .282 | 73 (63-90) | 72 (63-87) | .631 |
| Male | 121 (64) | 55 (62) | 110 (78) | .010 | 66 (65) | 74 (70) | .493 |
| Performance status >1 | 36/158 (23) | 16/77 (21) | 23/136 (17) | .483 | 20/81 (25) | 31/93 (33) | .212 |
| Elevated LDH | 40/140 (29) | 24/71 (34) | 45/127 (35) | .817 | 16/69 (23) | 31/83 (37) | .060 |
| Ann Arbor stage III/IV | 166/180 (92) | 79/84 (94) | 129/142 (91) | .390 | 87/96 (91) | 95/103 (93) | .685 |
| Marrow/blood involvement | 132 (69) | 65 (73) | 113 (80) | .250 | 67 (66) | 73 (69) | .697 |
| B symptoms | 41/180 (23) | 22/84 (26) | 46/142 (32) | .326 | 19/96 (20) | 26/103 (25) | .358 |
| Largest mass ≥5 cm | 52/109 (48) | 24/52 (46) | 60/123 (49) | .751 | 28/57 (49) | 46/85 (54) | .559 |
| MIPI | |||||||
| High risk | 21/125 (17) | 9/64 (14) | 14/122 (12) | .519 | 12/61 (20) | 31/74 (42) | .007 |
| Intermediate risk | 38/125 (30) | 14/64 (22) | 20/122 (16) | 24/61 (39) | 28/74 (38) | ||
| Low risk | 66/125 (53) | 41/64 (64) | 88/122 (72) | 25/61 (41) | 15/74 (20) | ||
| Blastoid/pleomorphic | 13 (7) | 7 (8) | 14 (10) | .608 | 6 (6) | 15 (14) | .051 |
| Median Ki67 (range) | 30 (5-90) | 25 (5-90) | 25 (1-99) | .317 | 30 (5-90) | 33 (2-100) | .192 |
| Ki67 ≥30% | 92/171 (54) | 36/80 (45) | 42/88 (48) | .723 | 56/91 (62) | 34/64 (53) | .296 |
| Ki67 ≥50% | 45/171 (26) | 17/80 (21) | 26/88 (30) | .218 | 28/91 (31) | 22/64 (34) | .636 |
| Prior observation | 21 | 7 (8) | 6 (4) | .243 | 14 (14) | 6 (6) | .046 |
| Prior local therapy | 6 | 1 (1) | 3 (3) | 1.0 | 5 (5) | 1 (1) | .112 |
| Median no. of chemotherapy cycles (range) | 6 (1-6) | 6 (1-6) | 6 (1-8) | .127 | 6 (1-6) | 6 (1-8) | .890 |
| ≥6 cycles of chemotherapy | 154 (81) | 78 (88) | 123 (87) | .822 | 76 (75) | 82 (77) | .721 |
| ASCT | 71 (37) | 61 (69) | 81 (57) | .081 | 10 (10) | 5 (5) | .150 |
| Rituximab maintenance | 141 (74) | 72 (81) | 80 (56) | <.001 | 72 (71) | 25 (24) | <.001 |
| Rituximab maintenance protocol | |||||||
| Weekly × 4 doses ×2 cycles | 31/141 (22) | 27/72 (37) | 73/80 (91) | <.001 | 5/72 (7) | 5/25 (20) | .064 |
| Every 3 mo ×8 cycles | 110/141 (78) | 45/72 (63) | 7/80 (9) | 67/72 (93) | 20/25 (80) | ||
Values in the table body are shown as n (%) or n/N (%), unless otherwise stated in row headings.